Preparation and evaluation of a Carbopol®/HPMC-based in situ gelling ophthalmic system for puerarin

Yakugaku Zasshi

Volumn 127, Issue 1, 2007, Pages 183-191

  Wu, Chunjie ^a   Qi, Hongyi ^a   Chen, Wenwen ^a   Huang, Chunyan ^a   Su, Cheng ^a   Li, Wenmin ^a   Hou, Shixiang ^b  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Carbopol ; HPMC; Hydroxypropyl cyclodextrin (HP CD); in situ gelling; Ophthalmic delivery system; Puerarin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CARBOMER; METHYLCELLULOSE; PUERARIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; FLOW KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH MEASUREMENT;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE PERMEABILITY; CORNEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GELS; HYDROGEN-ION CONCENTRATION; ISOFLAVONES; MALE; METHYLCELLULOSE; OPHTHALMIC SOLUTIONS; POLYMERS; POLYVINYLS; RABBITS; SOLUBILITY; VASODILATOR AGENTS; VISCOSITY;

EID: 33846141485     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.127.183     Document Type: Article

References (22)

1. State Pharmacopoeia Commission of P. R. China, "Pharmacopoeia of the People's Republic of China, Vol. 2," Chemical Industry Press, Beijing, 2005, p. 688.
2. Zhang J. Q., Zhou Y. P., Zhong Guo Zhong Yao Za Zhi, 14, 557-559, 576 (1989).
3. Xuan B., Zhou Y. H., Yang R. L., Li N., Min Z. D., Chiou G. C., J. Ocul. Pharmacol. Ther., 15, 207-216 (1999).
4. Ren P., Hu H., Zhang R., Zhong Guo Zhong Xi Yi Jie He Za Zhi, 20, 574-576 (2000).
5. Wu Z. H., Liu Y. Q., Zhu Y. Q., Yan H. Y., J. China Pharm. Univ., 29, 387-389 (1998).
6. Cohen S., Lobel E., Trevgoda A., Peled Y., J. Control. Release, 44, 201-208 (1997).
7. Lin H. R., Sung K. C., J. Control. Release, 69, 379-388 (2000).
8. Edsman K., Carlfors J., Petersson R., Eur. J. Pharm. Sci., 6, 105-112 (1998).
9. Srividya B., Cardoza R. M., Amin P. D., J. Control. Release, 73, 205-211 (2001).
10. Ceulemans J., Ludwig A., Eur. J. Pharm. Biopharm., 54, 41-50 (2002).
11. Liu Z., Li J., Nie S., Liu H., Ding P., Pan W., Int. J. Pharm., 315, 12-17 (2006).
12. Choi H. G., Kim D. D., Jun H. W., Yoo B. K., Yong C. S., Drug Dev. Ind. Pharm., 29, 1085-1094 (2003).
13. Loftssona T., Jäarvinen T., Adv. Drug. Del. Rev., 36, 59-79 (1999).
14. Higuchi T., Lach J. L., J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim), 43, 349-354 (1954).
15. Montenegro L., Bucolo C., Puglisi G., Pharmazie, 58, 497-501 (2003).
16. Romanelli L., Valeri P., Morrone L. A., Life Sci., 54, 877-885 (1994).
17. Saettone M. F., Chetoni R., Int. J. Pharm., 142, 103-113 (1996).
18. Hagerstrom H., Paulsson M., Edsman K., Eur. J. Pharm. Sci., 9, 301-309 (2000).
19. Higuchi T., Kristiansen H., J. Pharm. Sci., 59, 1601-1608 (1970).
20. Castillo J. A., Palomo-Canales J., Garcia J. J., Drug Dev. Ind. Pharm., 25, 1241-1248 (1999).
21. Wu Z. H., Zhu Y. Q., Yan H. Y., Jiangsu Pharm. Clin. Res., 7, 9-11 (1999).
22. Kumar S. R., Himmestein K. J., J. Pharm. Sci., 84, 344-348 (1995).